Program: Saturday (22.10.2016)

08:30 – 12:00

Hematology Educational Hematology Educational

  • Martin Dreyling
  • Anton Hagenbeek
  • 08:30–08:35

    Introduction

    • Martin Dreyling
    • Anton Hagenbeek
  • 08:35–09:10

    Chronic Lymphocytic Leukemia (CLL)

    • Michael Hallek
  • 09:10–09:45

    Mantle Cell Lymphoma (MCL)

    • Martin Dreyling
  • 09:45–10:20

    Aggressive Non-Hodgkin Lymphoma

    • Wyndham Wilson
  • 10:20–10:50

    Coffee break

  • 10:50–11:25

    Follicular Lymphoma (FL)

    • Anton Hagenbeek
  • 11:25–12:00

    Multiple Myeloma (MM)

    • Christoph Scheid

09:00 – 10:30

Workshop New Concepts of Radiation Field Design, Advanced Technologies and New Normal Organ Constraints

  • Richard Hoppe
  • Joachim Yahalom
  • Radiation eld reduction beyond ISRT? – options and concerns

    • George Mikhaeel
  • Avoidance of organs at risk / dose-volume constraints – deep inspiration breath hold: techniques and daily monitoring

    • David Hodgson
  • Avoidance of organs at risk / dose-volume constraints – dose / volume constrains for key organs at risk

    • Berthe Aleman

09:00 – 10:30

Workshop Epidemiology and Registry Data

  • Magnus Björkholm
  • Nelson Spector
  • Welcome and short introduction

    • Nelson Spector
    • Magnus Björkholm
  • Experience from the international T cell project

    • Massimo Federico
  • Registry studies on Hodgkin Lymphoma – the US experience

    • Rahul Parikh
  • Registry-based studies on socio-economic impact on outcome in Hodgkin Lymphoma in Brazil

    • Irene Biasoli
  • Registry-based studies on pregnancy in Hodgkin Lymphoma patients

    • Caroline Weibull
  • Registry-based research – pros and cons – the statistician’s view

    • Paul Dickman
  • General discussion

10:45 – 12:15

Workshop Pathology and Pathogenesis

  • Anke van den Berg
  • Andreas Rosenwald
  • Risk and prognosis in Hodgkin Lymphoma and associations with an active, innate or anergic tumor immune response

    • Ingrid Glimelius
  • NF-KB / IRF5 in Hodgkin Lymphoma

    • Stephan Mathas
  • Noncoding RNAs and microRNA in Hodgkin Lymphoma

    • Joost Kluiver

10:45 – 12:15

Workshop PET

  • Bruce Cheson
  • Martin Hutchings
  • Pretreatment stage or metabolic volume: which is better to direct treatment strategy?

    • Michel Meignan
  • Response assessment in the era of checkpoint inhibitors

    • Philippe Armand

12:45 – 13:45

Satellite Symposium (by Celgene GmbH) Recent Advances in the Treatment of Lymphoma

  • Andreas Engert
  • The FLASH project: establishing a novel surrogate endpoint in first-line FL

    • Wolfgang Hiddemann
  • Update on clinical data of IMiDs® in the treatment of lymphoma

    • Pier Luigi Zinzani

14:00 – 15:30

Workshop Biomarkers

  • Christian Steidl
  • Bastian von Tresckow
  • Methodological issues of circulating cell-free DNA detection in HL

    • Peter Vandenberghe
  • Outcome prediction of aSCT using Hodgkin Lymphoma relapse biopsies

    • Fong Chun Chan
  • Nanostring-based outcome prediction in HL patients treated with BEACOPP

    • Andreas Rosenwald
  • Integration of IPS factors with gene expression for treatment outcome prediction

    • Catherine Diefenbach
  • Biomarkers / companion diagnostics for checkpoint inhibition

    • Stephen Ansell

14:00 – 15:30

Workshop Elderly Patients

  • Boris Böll
  • Jonathan Friedberg
  • US experience in elderly HL

    • Andrew Evens
  • European experience in elderly HL

    • Marc André
  • Geriatric assessment

    • Ulrich Wedding
  • Trials on Brentuximab Vedotin and checkpoint inhibitors in elderly HL

    • Jonathan Friedberg
  • Population based data on elderly HL

    • Magnus Björkholm

14:00 – 15:30

Workshop GHSG Workshop

  • Michael Fuchs
  • Andreas Engert

16:00 – 17:30

Workshop Genetics and Microenvironment

  • Ralf Küppers
  • Margaret Shipp
  • Molecular pathogenesis of NLPHL

    • Sylvia Hartmann
  • The B cell receptor speci city of LP cells in NLPHL

    • Lorenz Thurner
  • Hodgkin cell-derived extracellular vesicles shape broblast activity

    • Teresa Bösl
  • The lymphoid cell speci c transcription factor ELF-1 is downregulated and deleted in classical Hodgkin lymphoma

    • Maciej Giefing
  • Tightly regulated FOXO3 expression is critical for the maintenance of cHL

    • Clarissa Weitzer

16:00 – 17:30

Workshop NLPHL

  • Joseph Connors
  • Andreas Engert
  • Update on classi cation of NLPHL and its distinction from TCRBCL and transformed DLBCL

    • Nancy L. Harris
  • Latest GHSG data on NLPHL

    • Dennis Eichenauer
  • Case studies of patients with “apparent” relapse of NLPHL

    • Joseph Connors

16:00 – 17:30

Workshop Late Effects

  • Lena Specht
  • Flora van Leeuwen
  • Influence of radiotherapy and chemotherapy in modern Hodgkin Lymphoma treatment on risks of cardiovascular disease and second malignancy

    • Lena Specht
  • Reducing cardiovascular risk in Hodgkin Lymphoma survivors – the SECURE trial

    • John Radford
  • Phase 2 trial comparing the feasibility and efficacy of physical activity and multifactorial drug treatment in Hodgkin Lymphoma survivors

    • Flora van Leeuwen

17:45 – 19:15

Satellite Symposium (by Novartis Pharma GmbH (Oncology)) Into the Future – New Treatment Options for Hematologic Malignancies

  • Peter Borchmann
  • 17:45–17:50

    Welcome

    • Peter Borchmann
  • 17:50–18:05

    Midostaurin – a novel therapeutic approach for patients with FLT3-mutated AML

    • Thomas Fischer
  • 18:05–18:20

    The concept of treatment-free remission in CML – results from current studies

    • Alexander Kiani
  • 18:20–18:35

    Panobinostat for relapsed or refractory myeloma: pan-HDAC-inhibition with epigenetic e ects

    • Andreas Günther
  • 18:35–19:20

    Advances in the treatment of hematologic malignancies: use of CAR T cells

    • Peter Borchmann

Archive

You a viewing the program of a past symposium. Click here to get back to the current conference.